There are currently 651 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Recruiting
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Site US10018, Charleston, South Carolina
Conditions: Prostate Cancer
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
Recruiting
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/11/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Oropharyngeal Squamous Cell Carcinoma
Phase III Study of AK112 for NSCLC Patients
Recruiting
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Medical University South Carolina, Charleston, South Carolina
Conditions: Non-Squamous Non-small Cell Lung Cancer
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
Recruiting
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not responded to previous RET directed therapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selpercatinib may st... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Ralph H Johnson VA Medical Center, Charleston, South Carolina +1 locations
Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Medical University of South Carolina - Nexus Research Center, Charleston, South Carolina
Conditions: Pulmonary Arterial Hypertension
REBYOTA™ Prospective Registry
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Ferring Investigational Site, Charleston, South Carolina
Conditions: Recurrence of Clostridium Difficile Infection
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Recruiting
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/10/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Zenith® Fenestrated+ Clinical Study
Recruiting
The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/10/2024
Locations: Medical University of South Carolina University Hospital, Charleston, South Carolina
Conditions: Intracerebral Hemorrhage
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
Recruiting
This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. Participants take a low, medium, or high dose of BI... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Bronchiectasis
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
Recruiting
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
Gender:
All
Ages:
All
Trial Updated:
06/10/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Aortic Stenosis
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Recruiting
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months f... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
06/10/2024
Locations: Medical Uni of South Carolina Medical Univ of SC, Charleston, South Carolina
Conditions: B-Cell Acute Lymphoblastic Leukemia